EMA Authorised: Herwenda (trastuzumab) — Sandoz GmbH

View source ↗

Summary

EMA authorised Herwenda, a trastuzumab biosimilar by Sandoz GmbH, for certain HER2-positive cancers. Approved indications include breast cancer and gastric canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer

Drugs mentioned

• Herwenda (trastuzumab)

Snippet

Status: Authorised. Therapeutic area: Breast Neoplasms;Stomach Neoplasms. MAH: Sandoz GmbH. Decision date: 04/09/2025